| Literature DB >> 34011962 |
Yo-Ping Lai1, Lu-Cheng Kuo1, Been-Ren Lin2, Hung-Ju Lin1, Chih-Yu Lin3, Yi-Ting Chen4, Pei-Wen Hsiao3, Huan-Tsung Chang5, Patrick Chow-In Ko6, Hsiao-Chin Chen7, Hsiang-Yu Chang5, Jean Lu8,9,10, Hong-Nerng Ho11,12, Betty A Wu-Hsieh12, John T Kung4, Shu-Ching Chen13.
Abstract
CD28 is required for T cell activation as well as the generation of CD4+Foxp3+ Treg. It is unclear, however, how CD28 costimulation affects the development of CD8+ T cell suppressive function. Here, by use of Hepa1.6.gp33 in vitro killing assay and B16.gp33 tumor mouse model we demonstrate that CD28 engagement during TCR ligation prevents CD8+ T cells from becoming suppressive. Interestingly, our results showed that ectonucleotidase CD73 expression on CD8+ T cells is upregulated in the absence of CD28 costimulation. In both murine and human tumor-bearing hosts, CD73 is upregulated on CD28-CD8+ T cells that infiltrate the solid tumor. UPLC-MS/MS analysis revealed that CD8+ T cells activation without CD28 costimulation produces elevated levels of adenosine and that CD73 mediates its production. Adenosine receptor antagonists block CD73-mediated suppression. Our data support the notion that CD28 costimulation inhibits CD73 upregulation and thereby prevents CD8+ T cells from becoming suppressive. This study uncovers a previously unidentified role for CD28 costimulation in CD8+ T cell activation and suggests that the CD28 costimulatory pathway can be a potential target for cancer immunotherapy.Entities:
Year: 2021 PMID: 34011962 DOI: 10.1038/s42003-021-02119-9
Source DB: PubMed Journal: Commun Biol ISSN: 2399-3642